Stemline Therapeutics, Inc. (NASDAQ:STML) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
Several other research analysts also recently commented on STML. Cowen and Company reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research note on Wednesday, June 14th. HC Wainwright reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research note on Monday, May 15th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Stemline Therapeutics in a research note on Thursday, May 25th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Stemline Therapeutics in a research note on Saturday, March 25th. Finally, ValuEngine cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 31st. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $29.17.
Stemline Therapeutics (NASDAQ STML) opened at 9.836 on Tuesday. Stemline Therapeutics has a one year low of $5.50 and a one year high of $14.60. The stock’s market cap is $229.93 million. The stock’s 50 day moving average price is $8.68 and its 200 day moving average price is $8.80.
Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.22. Stemline Therapeutics had a negative return on equity of 60.51% and a negative net margin of 3,864.20%. The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.30 million. Equities analysts predict that Stemline Therapeutics will post ($2.27) earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in STML. FMR LLC boosted its stake in Stemline Therapeutics by 72.1% in the first quarter. FMR LLC now owns 2,538,892 shares of the biopharmaceutical company’s stock valued at $21,708,000 after buying an additional 1,063,457 shares in the last quarter. Eventide Asset Management LLC boosted its stake in Stemline Therapeutics by 27.6% in the first quarter. Eventide Asset Management LLC now owns 1,086,400 shares of the biopharmaceutical company’s stock valued at $9,289,000 after buying an additional 235,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Stemline Therapeutics by 32.9% in the first quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock valued at $7,055,000 after buying an additional 204,228 shares in the last quarter. AXA acquired a new stake in Stemline Therapeutics during the first quarter valued at about $3,712,000. Finally, Sphera Funds Management LTD. acquired a new stake in Stemline Therapeutics during the first quarter valued at about $2,565,000. Hedge funds and other institutional investors own 54.18% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Get a free copy of the Zacks research report on Stemline Therapeutics (STML)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
